Drug Trial Radar · NCT01853072
Nepafenac Once Daily for Macular Edema - Study 1
Last checked: Nov 20, 2026Latest source record: Aug 3, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
881
Actual
Start
Jun 2013
Primary completion
May 2015
Study completion May 2015
Sponsor
- Lead sponsor
- Alcon ResearchIndustry
- Sponsor type
- Industry
- First posted
- May 14, 2013
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to demonstrate superiority of Nepafenac Ophthalmic Suspension, 0.3% dosed once daily relative to Nepafenac Vehicle based upon clinical outcomes among diabetic subjects following cataract surgery.
Conditions
- Non-Proliferative Diabetic Retinopathy
- Cataract
Interventions
Nepafenac Ophthalmic Suspension, 0.3%Drug
Test intervention
Nepafenac vehicleOther
Inactive ingredients used as placebo comparator
Prednisolone acetateDrug
1 drop instilled in the operative eye 4 times daily beginning post-operatively on the day of surgery for the first 2 weeks, followed by 2 times daily for the next 2 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Best-corrected Visual Acuity (BCVA) Improvement of ≥ 15 Letters From Preoperative Baseline to Day 14 and Maintained Through Day 90Time frame: Baseline to Day 14, and maintained through Day 90
- Percentage of Participants Who Develop Macular Edema Within 90 Days Following Cataract Surgery (Day 0)Time frame: Day 0 to Day 90
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.